CN109432448B - Gastrointestinal contrast agent for X-ray examination - Google Patents
Gastrointestinal contrast agent for X-ray examination Download PDFInfo
- Publication number
- CN109432448B CN109432448B CN201811449670.6A CN201811449670A CN109432448B CN 109432448 B CN109432448 B CN 109432448B CN 201811449670 A CN201811449670 A CN 201811449670A CN 109432448 B CN109432448 B CN 109432448B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- contrast agent
- mannitol
- ray examination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0404—X-ray contrast preparations containing barium sulfate
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A gastrointestinal contrast agent for X-ray examination is characterized by comprising 300-400 parts by weight of barium sulfate, 10-20 parts by weight of mannitol, 0.3-0.5 part by weight of curcumin, 2-3 parts by weight of acetic acid and 0-300 parts by weight of water.
Description
Technical Field
The invention relates to a contrast agent for X-ray examinations.
Background
During the X-ray radiography examination of the digestive tract, because the density of organs and tissues of the abdomen is similar, a contrast agent which is harmless to a human body, such as barium and other elements with large atomic coefficients, must be introduced, and the elements and the X-rays have photoelectric effect, so that the characteristic X-rays can be radiated to penetrate through the tissues of the human body to reach a film to form fog, the display contrast is artificially improved, and the ideal examination effect can be achieved. Therefore, barium sulfate or the like is often used as a contrast medium. However, due to the complexity of the human digestive tract, when the barium sulfate (barium meal) is taken orally as a contrast agent, the contrast effect on the upper digestive tract is better. The colorectal cavity in the lower digestive tract may be filled with contrast enemas. However, in the ileocecal part of the lower digestive tract, the conventional contrast agent is adopted, so that the problems of poor contrast effect, long waiting time after the contrast agent is taken and the like exist, in the prior art, the mannitol is taken together to promote the movement of the contrast agent in the intestinal tract, but the mannitol belongs to a high osmotic pressure medicament, and can cause certain stimulation to the intestinal tract in the intestinal tract, especially when a patient suffers from diseases such as colitis, the exacerbation of colon inflammation can be caused, and diarrhea can be caused. Therefore, it is an urgent problem in the prior art to provide a gastrointestinal contrast agent for X-ray that can reach the ileocecal area quickly, can produce a good contrast effect, does not irritate the colon area that has already suffered from colitis, and is not likely to cause diarrhea.
Disclosure of Invention
In the research, the inventor finds that after the mannitol is used for preparing the gastrointestinal contrast agent by reducing the dosage and adding a small amount of acetic acid dissolved in curcumin and mixing with barium sulfate, the gastrointestinal contrast agent can quickly reach the ileocecal part and produce good contrast effect, and can avoid the stimulation of the conventional mannitol to the colon part with the colitis.
The technical scheme provided by the invention is as follows: disclosed is a gastrointestinal contrast agent for X-ray examination, which is characterized in that the contrast agent comprises 300-400 parts by weight of barium sulfate, 10-20 parts by weight of mannitol, 0.3-0.5 part by weight of curcumin, 2-3 parts by weight of acetic acid and 0-300 parts by weight of water,
the gastrointestinal contrast agent for X-ray examination is characterized by comprising 300-400 parts by weight of barium sulfate, 10-15 parts by weight of mannitol, 0.3-0.5 part by weight of curcumin, 2-3 parts by weight of acetic acid and 200-250 parts by weight of water.
The gastrointestinal contrast agent for X-ray examination is characterized by being prepared by the following method:
dissolving curcumin in acetic acid, adding mannitol, adding water and barium sulfate, and stirring.
The invention provides a gastrointestinal contrast agent, which increases a small amount of curcumin dissolved in acetic acid under the condition of reducing the using amount of mannitol. Furthermore, no irritation was shown in the colon of colitis model mice. The gastrointestinal contrast agent provided by the invention is used for rapidly advancing in the intestinal tract to reach the ileocecal part as soon as possible, and has no irritation to the colon with colitis symptoms, so that the colonic inflammation is not aggravated. And a comparison experiment shows that the effect of the contrast agent can be obviously improved after a small amount of curcumin dissolved in acetic acid is matched with mannitol, a synergistic effect is generated, and the effect of the contrast agent can be adversely affected by changing a prescription.
Detailed Description
Preparation method
Dissolving curcumin in acetic acid, adding mannitol, adding water and barium sulfate, and stirring.
Examples and comparative example formulations are given in the following table (unit: parts by weight)
Pharmacological examples
Healthy SD mice (about 10 months old) weighing 180-220 g. Gender was maintained in an air-conditioned room and fed with standard pellet feed, free water and food intake.
Molding die
After the rats are fasted for 24 hours and are lightly anesthetized by ether, a silicone tube with the outer diameter of 2mm is inserted into the anus of the rats for about 8cm, 2ml of 10% acetic acid solution is injected into the tube, 5ml of physiological saline is injected after 10-20 seconds to eliminate the effect of acetic acid, the rats are placed back into a cage for normal feeding after being naturally awake to finish molding, the molded rats are divided into an experimental group 1-7 and a control group, 10 rats are arranged in each group, the administration mode is that the contrast agents obtained in the embodiments 1-6 and the comparative examples are filled with stomach for administration, and water is forbidden after administration.
Groups and administration groups are shown in the following Table
Small intestine propulsion rate experiment
After administration for 45min, 5 test animals per group were sacrificed and the abdominal cavity was opened, the intestine from the upper end to the pylorus and from the lower end to the ileocecal portion was gently extracted with forceps and placed on a tray, the small intestine was gently pulled into a straight line, and the index of small intestine propulsion was measured with a ruler. The calculated percent small bowel advancement is calculated by the following equation: the small intestine propulsion rate is the distance (cm) from the front end of the contrast agent to the pyloric sphincter/the distance (cm) from the pyloric sphincter to the small intestine end x 100%. (wherein the small intestine propulsion movement rate was regarded as 100% by the time the contrast medium reached the ileocecal part), the small intestine propulsion rate data of 5 experimental animals per group were as follows (in%)
The experimental result shows that the contrast agent provided by the invention can reach the ileocecal part more quickly by stomach filling compared with the comparative example, and in the experimental groups 1-6, the small intestine propulsion movement rate of the experimental group 1/3/5/6 is higher than that of the experimental group 2/4, which indicates that the preferable addition amount of mannitol can better realize the effect of accelerating the small intestine propulsion rate and leading the contrast agent to reach the ileocecal part as soon as possible.
Colon inflammation scoring
The remaining 5 animals in each group started to eat water freely 45min after administration, were raised until the contrast agent was completely eliminated (black stool was eliminated), dissected, observed for colonic mucosa, and scored for colonic mucosa injury, with the following scoring criteria:
0 mucous membrane without edema, congestion and ulcer, intestinal wall without adhesion and hyperplasia
1 mild mucosal edema, hyperemia, no ulcer
2 congestion, edema, erosion, and ulcer of mucous membrane
Congestion, edema, erosion, single ulcer of mucous membrane
Congestion, edema, erosion, multiple ulcers of mucous membrane
5 mucosal congestion, edema, severe erosion, multiple ulcers, with >1cm of ulcers
The scoring results are as follows
The experimental results show that compared with the experimental group 7/8 which adopts the control group, the mucosal damage of the experimental animals of the experimental groups 1-6 which adopt the contrast agent provided by the invention is reduced to some extent. The contrast agent provided by the invention is less likely to cause aggravation of colon inflammation and less irritant to colitis patients.
Claims (4)
1. A gastrointestinal contrast agent for X-ray examination, characterized in that the contrast agent consists of 400 parts by weight of barium sulfate, 10 parts by weight of mannitol, 0.5 parts by weight of curcumin, 2 parts by weight of acetic acid and 250 parts by weight of water.
2. A gastrointestinal contrast agent for X-ray examination, characterized in that the contrast agent consists of 300 parts by weight of barium sulfate, 10 parts by weight of mannitol, 0.5 parts by weight of curcumin, 2 parts by weight of acetic acid and 250 parts by weight of water.
3. A gastrointestinal contrast agent for X-ray examination, characterized in that the contrast agent consists of 300 parts by weight of barium sulfate, 15 parts by weight of mannitol, 0.5 parts by weight of curcumin, 3 parts by weight of acetic acid and 250 parts by weight of water.
4. A gastrointestinal contrast agent for X-ray examination, characterized in that the contrast agent consists of 400 parts by weight of barium sulfate, 15 parts by weight of mannitol, 0.3 parts by weight of curcumin, 2 parts by weight of acetic acid and 250 parts by weight of water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811449670.6A CN109432448B (en) | 2018-11-29 | 2018-11-29 | Gastrointestinal contrast agent for X-ray examination |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811449670.6A CN109432448B (en) | 2018-11-29 | 2018-11-29 | Gastrointestinal contrast agent for X-ray examination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109432448A CN109432448A (en) | 2019-03-08 |
| CN109432448B true CN109432448B (en) | 2021-07-23 |
Family
ID=65555990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811449670.6A Expired - Fee Related CN109432448B (en) | 2018-11-29 | 2018-11-29 | Gastrointestinal contrast agent for X-ray examination |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432448B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003086172A2 (en) * | 2002-04-06 | 2003-10-23 | E-Z-Em, Inc. | Method for tagging colonic residue |
| JP6441678B2 (en) * | 2012-11-09 | 2018-12-19 | Ｅａファーマ株式会社 | Solution for oral administration and composition for gastrointestinal tract imaging used for CT colonography |
| CN104491884B (en) * | 2014-12-04 | 2017-08-25 | 济南市儿童医院 | A kind of gastrointestinal contrast agent containing traditional Chinese medicine ingredients |
| CN105534962A (en) * | 2015-12-24 | 2016-05-04 | 泸州医学院附属医院 | Model establishment method of effect of curcumin on mouse UC (ulcerative colitis) PPAR-gamma and COX-2 induced by DSS (dextran sulphate sodium) |
-
2018
- 2018-11-29 CN CN201811449670.6A patent/CN109432448B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN109432448A (en) | 2019-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230026686A1 (en) | Ascaroside treatment of eosinophilic esophagitis | |
| White et al. | Stomach function in relation to a scour syndrome in the piglet | |
| CN109432447B (en) | Contrast agent for X-ray examination of the digestive tract | |
| WO2020186804A1 (en) | Gastrointestinal ultrasonographic developer and preparation method therefor | |
| CN109432448B (en) | Gastrointestinal contrast agent for X-ray examination | |
| EP0360266B1 (en) | Barium sulfate contrast medium for x-ray examination of the large intestine | |
| Low et al. | Meconium peritonitis | |
| Elebute et al. | Patent vitello-intestinal duct with ileal prolapse | |
| Chaet et al. | Management of multiple jejunoileal atresias with an intraluminal SILASTIC® stent | |
| Obetti et al. | Emphysematous cystitis and bladder trigone diverticulum in a dog | |
| Pugh et al. | Multiple polypoid disease of the colon and rectum | |
| CN1270776C (en) | Ulcer quieting medicine its preparation and use | |
| CN112870382B (en) | Combination of arabinose and silicone oil defoamer for intestinal tract preparation | |
| Haupt et al. | Surgical treatment of colic in the miniature horse: a retrospective study of 57 cases (1993–2006) | |
| CN1231217C (en) | Medicine for treating climacteric syndrome | |
| Vignoli et al. | Gastrointestinal tract | |
| Malm et al. | Canine cricopharyngeal achalasia: case report | |
| CN112336879A (en) | Contrast barium sulfate jelly and preparation method thereof | |
| MacKellar et al. | Congenital diverticulum of the pharynx simulating esophageal atresia | |
| CN115887786B (en) | Polyvinylidene fluoride coated nano composite pipe and preparation method thereof | |
| Press Jr et al. | Ingested foreign bodies simulating polyposis: report of six cases | |
| Gezer et al. | A case of simultaneously detected rectovaginal fistula and atresia ani in a kitten. | |
| Frost et al. | The role of percutaneous endoscopic gastrostomy in spinal cord injured patients | |
| Quevedo et al. | S2025 Eosinophilic Enterocolitis Improved After Breast Reduction | |
| Yadegari et al. | Iodixanol as a gastrointestinal contrast media in the New Zealand white rabbit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yu Meihong Inventor after: Li Kaixuan Inventor after: Zhou Hejun Inventor after: Kong Lingqin Inventor before: Kong Lingqin |
|
| CB03 | Change of inventor or designer information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210706 Address after: No. 410011, Furong Middle Road, Changsha City, Hunan Province Applicant after: THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH University Address before: 300457 2nd floor, building 8, TEDA Service Outsourcing Industrial Park, 19 Xinhuan West Road, Binhai New Area Development Zone, Tianjin Applicant before: TIANJIN KAIYIN TECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210723 Termination date: 20211129 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |